Skip to content
Medical Health Aged Care

Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

Ad Scientiam 2 mins read

PARIS, FRANCE / ACCESSWIRE / September 12, 2023 / Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot®, a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam's expertise in MS and is financially supported by Sanofi.

AdS logo
AdS logo

Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot®, a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.

MS-DETECT's main objective is to determine MSCopilot®'s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot® individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.

"MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS," according to Dr. Saad Zinaï, Chief Medical Officer at Ad Scientiam.

"Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients," explains Su-Peing Ng, Global Head of Medical Affairs - Specialty Care at Sanofi.

The study also aims to assess the MSCopilot® performance, safety, usability and satisfaction with the solution.

"Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients' care," said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.

The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.

Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com

Contact Information

Saad Zinaï
Chief Medical Officer
szinai@adscientiam.com
+33768008666

Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666

SOURCE: Ad Scientiam

.


View source version on accesswire.com:
https://www.accesswire.com/782728/ad-scientiam-launches-international-study-to-assess-disability-progression-in-multiple-sclerosis-with-mscopilot

More from this category

  • Medical Health Aged Care
  • 26/05/2024
  • 07:25
Royal Australian College of GPs

RACGP ready to take on Far North Queensland GP training

The Royal Australian College of GPs (RACGP) has emphasised its readiness to prepare GPs to serve the north of the state. In February, the College said it was ready to take on GP training in the region after James Cook University announced it would transition away from GP training in 2024. Training will officially change over to the RACGP on 10 June, after extensive preparation and careful management to ensure a seamless transition. The College will continue existing training agreements with registrars, supervisors, and practices for the remainder of 2024. In 2023, the College successfully managed the onboarding of GP…

  • Contains:
  • Medical Health Aged Care
  • 26/05/2024
  • 04:31
Dementia Australia

Join us TODAY for Brisbane Memory Walk & Jog

What: Dementia Australia’sBrisbane Memory Walk & Jog When: Sunday 26 May, from 7.30am Who: More than 1,110 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Special guests Dementia Australia Ambassadors Wally Lewis AM and Takaya Honda. Where: Rocks Riverside Park, Seventeen Mile Rocks For more information visit: www.memorywalk.com.au Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We…

  • Contains:
  • Medical Health Aged Care
  • 26/05/2024
  • 04:30
Dementia Australia

Join us TODAY for Perth Memory Walk & Jog

What: Dementia Australia’sPerth Memory Walk & Jog When: Sunday 26 May, from 7.30am Who: More than 880 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Where: Burswood Park, Burswood. For more information visit: www.memorywalk.com.au Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.